How to Sidestep the Excellence Trap

Published: September 26, 2013

How to Sidestep the Excellence Trap

Rita Gunther McGrath, author of The End of Competitive Advantage: How to Keep Your Strategy Moving as Fast as Your Business, introduces a passage about when—and when not—to demand excellence from Tipping Sacred Cows: Kick the Bad Work Habits That Masquerade as Virtues, by Jake Breeden.

“Don’t bring me any surprises. Don’t bring me a problem without a solution.” Do these phrases sound familiar? They are manifestations of a managerial mind-set that Jake Breeden rightly calls out in his new book, Tipping Sacred Cows, as an unhealthy obsession with excellence. The demand that employees get everything right is deadly for innovation, experimentation, and discovery. When excellence is defined as living in a world of no surprises, you aren’t going to get any…until it’s too late. Read more of this post

Abby Johnson, the rarely seen face of Fidelity; The quiet billionaire has taken the reins of a former fund juggernaut but given few signs of where she’ll take it

Abby Johnson, the rarely seen face of Fidelity

Thursday, October 24, 10:35 AM

When Abigail Johnson began her apprenticeship at Fidelity Investments 25 years ago, the Boston-based firm founded by her grandfather was the nation’s biggest mutual fund company and star manager Peter Lynch was enjoying a performance streak at the Magellan Fund — a 29 percent average return over 13 years — that ranks among the best in the industry’s history. Read more of this post

Mark Dixon, the billionaire founder of Regus, the world’s largest operator of serviced offices, has more than doubled his fortune in the past year as increased demand for flexible office space propelled the company’s share price to all-time high

Billionaire Doubles Fortune on Workspace Demand Surge

Mark Dixon, the billionaire founder of Regus Plc (RGU), the world’s largest operator of serviced offices, has more than doubled his fortune in the past year as increased demand for flexible office space propelled the company’s share price to an all-time high. Regus shares have surged 106 percent since last October, compared to a 30.3 percent gain in the FTSE 250 index. Dixon, 53, owns a 34.2 percent stake in the company valued at $1.1 billion, according to data compiled by Bloomberg. Read more of this post

The Cardiologist Who Spread Heart Disease

The Cardiologist Who Spread Heart Disease

Mehmood Patel still wakes up early, just as he did when he was a popular heart specialist seeing patients who waited hours for minutes of his time. Instead of surgical scrubs, he climbs into the khaki drabs of the Federal Correctional Complex in Oakdale, Louisiana. He leads health-conscious inmates on a morning walk, then cracks open one of the medical journals on his prison-approved reading list. Counseling fellow convicts to keep their blood pressure down is about the extent of the doctoring done by the man who once boasted he was the busiest cardiologist in the nation. Read more of this post

Cancer Radiation Rates Grow When Urologists Reap Profit

Cancer Radiation Rates Grow When Urologists Reap Profit

Urologists that buy their own equipment to provide expensive radiation treatment are much more probable to use it to treat prostate cancer even when its benefit for patients is unclear, research shows. Prostate cancer is the most common tumor diagnosed in the U.S., where an estimated 238,590 men were told they had the disease this year. While only about 12 percent, or 29,270 men, will die from it this year, all will have to decide how, and whether, they want to treat the cancer. Read more of this post

Return to Reaganomics Seen Reviving U.K. Biotechnology

Return to Reaganomics Seen Reviving U.K. Biotechnology

Though it has knowhow and wealth, the U.K. has never had much success creating biotechnology startups to rival such U.S. triumphs as Genentech Inc. and Amgen Inc. One explanation for this difference can be summed up in two words: Ronald Reagan. President Reagan’s overhaul of investment and tax rules at the dawn of the U.S. biotechnology industry in the early 1980s pushed pension funds toward riskier investments. That helped fuel the growth of giants including Genentech, today a unit of Roche Holding AG, and Amgen. Read more of this post

American Firms Find China Hard Work

October 24, 2013, 4:35 PM

American Firms Find China Hard Work

It’s hard to know whether things are getting better or worse for American businesses operating in China. One day they’re slammed for charging too much for coffee and just a couple days later, the president is praising them for providing insight into global economics. But if you ask American businesses how things are going, you’ll find that they have a long list of complaints about barriers to working in China. Read more of this post

%d bloggers like this: